Peptonic Medical (PMED) Q4 2024 earnings summary

Executive summary

• Entered US market with VagiVital, expanded Nordic presence with two new product launches, and completed strategic restructuring including divestment of Israeli subsidiary.

• Full-year revenue declined due to structural changes, but Nordic sales grew 76% year-over-year, reaching SEK 11.6 million.

• Bruttomarginal improved to 56% for the group, driven by product mix and process improvements.

Financial highlights

• Q4 2024 sales: SEK 4.4 million (down from SEK 6.8 million year-over-year); full-year sales: SEK 26.9 million (down from SEK 37.1 million).

• Q4 gross profit: SEK 2.6 million (up from SEK 0.7 million); gross margin 58% (up from 10%).

• Q4 operating result: SEK -26.7 million (vs. SEK -19.6 million); full-year operating result: SEK -58.6 million (vs. SEK -41.2 million).

• Q4 EPS: SEK -0.005 (vs. SEK -0.015); full-year EPS: SEK -0.017 (vs. SEK -0.04).

• Cash at year-end: SEK 3.7 million (down from SEK 15.1 million).

Outlook and guidance

• Entering 2025 with strong momentum from US expansion and new product launches in core markets.

• US launch of VagiVital Intimate Calming Gel planned for March 2025, with Active Glide to follow in autumn.